健择联合顺铂治疗晚期非小细胞肺癌临床观察

目的观察健择（GEM）联合顺铂（DDP）治疗晚期非小细胞肺癌（non-small cell lung csneer，NSCLC）的疗效和毒性反应。方法50例晚期非小细胞肺癌患者应用GP联合方案化疗，健择1000ms／m^2，静滴30min，第1，8天；顺铂25mg／m^2，静滴1h，第1—3天，每21d为1周期，至少2周期。结果全组完全缓解（CR）1例，部分缓解（PR）21例，总有效率为44．0％。中位生存期为11个月，1年生存率为40．0％。Ⅲ度和Ⅳ度白细胞减少症和血小板减少症发生率分别为18．0％和16．0％。结论健择联合顺铂治疗晚期NSCLC有较好的疗效，且安全耐受性较好。

Clinical observation of gemcitabine and cisplatine in the treatment of advanced non-small cell lung cancer

Objective To observe the efficacy of combination regimen of gemcitabine and cisplatine （DDP） in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods Fifty patients with advanced NSCLC were treated with GP （gemzar 1 000 mg/m^2 d1, 8;DDP 25 mg/m^2d1-3 ）. The course was repeated every 3 weeks for at least 2 cycles. Results Of the 50 patients, 1 was CR, 21 were PR,the overall response rate was 44. 0%. The median survival time was 11 months, the 1-year survival rate was 40. 0%. The main toxic reactions were leukopenia（ incidence of 18.0% for grades Ⅲ ＋ Ⅳ ） and thrombocytopenia （incidence of 16.0% for grades Ⅲ＋ Ⅳ）. Conclusion The combination of gemcitabine and cisplatine is a feasible,well-tolerated and active scheme for treatment of advanced NSCLC.